← Back to Search

Stereotactic Body Radiation Therapy for Liver Cancer

Phase 2
Waitlist Available
Led By Nima Nabavizadeh
Research Sponsored by OHSU Knight Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights

Study Summary

This trial is testing whether Y-90 segmentectomy or stereotactic body radiation therapy is better in treating inoperable liver cancer.

Eligible Conditions
  • Liver Cancer
  • Hepatocellular Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of enrollment (enrollment rate)
Secondary outcome measures
Change in patient reported quality of life
Overall survival
Rate of liver transplant
+5 more

Side effects data

From 2022 Phase 2 trial • 29 Patients • NCT02045446
79%
Cough
64%
Nausea
64%
Dyspnea
57%
Fatigue
43%
Constipation
36%
Pain
36%
Dizziness
29%
Anemia
29%
Back pain
29%
Vomiting
21%
Lymphocyte count decreased
21%
Chest pain
21%
Death NOS
21%
Anorexia
21%
Anxiety
21%
Fall
14%
Depression
14%
Wheezing
14%
Hypotension
14%
Diarrhea
14%
Dysphagia
14%
Platelet count decreased
14%
Abdominal Pain
14%
Edema
14%
Fever
14%
Headache
14%
Insomnia
14%
Palpitations
7%
Dehydration
7%
Amnesia
7%
Dysuria
7%
Hearing impaired
7%
Hypertension
7%
Creatinine increased
7%
Dysgeusia
7%
Eye pain
7%
Confusion
7%
Hypernatremia
7%
Productive cough
7%
Dementia
7%
Hemorrhoids
7%
Pneumonitis
7%
White blood cell count decreased
7%
Throat pain
7%
Bone marrow biopsy
7%
Blurred vision
7%
Rash
7%
Tachycardia
7%
Lung infection
7%
Neuropathy
7%
Pleuritic pain
7%
Neutropenia
7%
Hypoxia
7%
Aspiration pneumonia
7%
Blood bilirubin increased
7%
Muscle weakness
7%
Tremor
7%
Weight loss
7%
Thrombocytopenia
7%
Floaters
7%
Toothache
7%
Sinusitis
7%
Alopecia
7%
Esophagitis
7%
Otitis externa
7%
Leukocytosis
7%
Edema limbs
7%
Gait disturbance
7%
Parathesia (tingling)
7%
Edema face
7%
COPD
100%
80%
60%
40%
20%
0%
Study treatment Arm
Stereotactic Body Radiation Therapy
Maintenance Chemotherapy

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm II (Y-90 radioembolization)Experimental Treatment3 Interventions
Patients receive Y-90 radioembolization via injection on day 1.
Group II: Arm I (SBRT)Experimental Treatment3 Interventions
Patients undergo SBRT every other day for a total of 5 days over 2 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic Body Radiation Therapy
2012
Completed Phase 2
~780

Find a Location

Who is running the clinical trial?

American Society of Clinical OncologyOTHER
33 Previous Clinical Trials
147,553 Total Patients Enrolled
Medical Research Foundation, OregonOTHER
12 Previous Clinical Trials
1,086 Total Patients Enrolled
Oregon Health and Science UniversityOTHER
966 Previous Clinical Trials
6,845,751 Total Patients Enrolled
1 Trials studying Liver Cancer
339 Patients Enrolled for Liver Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current openings for people who want to participate in this trial?

"This study, as indicated by clinicaltrials.gov, is not looking for any more participants at the moment. The trial was first posted on December 1st, 2022 and was last updated June 20th, 2022. There are 2694 other trials that patients can sign up for currently."

Answered by AI

What is the FDA's official position on Stereotactic Body Radiation Therapy?

"While Phase 2 trials are not as data-rich as later stages, there is some evidence to suggest that Stereotactic Body Radiation Therapy is safe."

Answered by AI
~0 spots leftby Jan 2026